Figure 5.
Antitumor activity of pazopanib in combination with TGase 2 inhibition against a CAKI-1 xenograft mouse model. After the subcutaneous injection of CAKI-1 cells (5 × 106 cells), mice were randomized into four groups (n = 5) and were treated with vehicle (control), streptonigrin (0.1 mg/kg), or pazopanib (100 mg/kg) as single agents or in combination. Drugs were administered 3 times a week every other day. (A) Tumor growth curves during the treatment period. Each point is the mean tumor volume in the group. (B) Tumors were isolated from the mice and weighed. (C) Body weights of mice during the treatment period. Each point is the mean weight of mice in each group. (D) Representative areas of CD31 IHC staining slides in CAKI-1 tumor xenograft from mice. (E) Average number of CD31-positive cells in CAKI-1 tumor xenograft from mice (n = 9). Error bar represent SD. GraphPad Prism software used to perform one-way or two-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Scale bar = 100 μm.